Genelux Corporation Common Stock (GNLX) - Net Assets
Based on the latest financial reports, Genelux Corporation Common Stock (GNLX) has net assets worth $22.92 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($32.37 Million) and total liabilities ($9.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GNLX tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $22.92 Million |
| % of Total Assets | 70.81% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 45.49 |
Genelux Corporation Common Stock - Net Assets Trend (2019–2025)
This chart illustrates how Genelux Corporation Common Stock's net assets have evolved over time, based on quarterly financial data. See how many days can Genelux Corporation Common Stock fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Genelux Corporation Common Stock (2019–2025)
The table below shows the annual net assets of Genelux Corporation Common Stock from 2019 to 2025. For live valuation and market cap data, see GNLX company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $11.54 Million | -56.06% |
| 2024-12-31 | $26.27 Million | +34.93% |
| 2023-12-31 | $19.47 Million | +154.42% |
| 2022-12-31 | $-35.78 Million | -8.07% |
| 2021-12-31 | $-33.11 Million | -46.15% |
| 2020-12-31 | $-22.66 Million | +8.69% |
| 2019-12-31 | $-24.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genelux Corporation Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12895300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $38.00K | 0.33% |
| Other Comprehensive Income | $9.00K | 0.08% |
| Other Components | $295.04 Million | 2555.74% |
| Total Equity | $11.54 Million | 100.00% |
Genelux Corporation Common Stock Competitors by Market Cap
The table below lists competitors of Genelux Corporation Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Coraza Integrated Technology Bhd
KLSE:0240
|
$127.80 Million |
|
Micro Systemation AB (publ)
ST:MSAB-B
|
$127.83 Million |
|
Mercator Medical S.A.
WAR:MRC
|
$127.85 Million |
|
Super Energy Corporation Public Company Limited
BK:SUPER-R
|
$127.87 Million |
|
UBM Development AG
VI:UBS
|
$127.77 Million |
|
DNF Co.Ltd
KQ:092070
|
$127.74 Million |
|
Thac Mo Hydropower JSC
VN:TMP
|
$127.66 Million |
|
ABL Group ASA
OL:ABL
|
$127.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genelux Corporation Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 26,274,000 to 11,544,000, a change of -14,730,000 (-56.1%).
- Net loss of 32,145,000 reduced equity.
- New share issuances of 9,657,000 increased equity.
- Other comprehensive income decreased equity by 55,000.
- Other factors increased equity by 7,813,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-32.15 Million | -278.46% |
| Share Issuances | $9.66 Million | +83.65% |
| Other Comprehensive Income | $-55.00K | -0.48% |
| Other Changes | $7.81 Million | +67.68% |
| Total Change | $- | -56.06% |
Book Value vs Market Value Analysis
This analysis compares Genelux Corporation Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.18x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-1.05 | $2.85 | x |
| 2020-12-31 | $-0.96 | $2.85 | x |
| 2021-12-31 | $-1.40 | $2.85 | x |
| 2022-12-31 | $-1.46 | $2.85 | x |
| 2023-12-31 | $0.80 | $2.85 | x |
| 2024-12-31 | $0.84 | $2.85 | x |
| 2025-12-31 | $0.31 | $2.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genelux Corporation Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -278.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -401812.50%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.65x
- Recent ROE (-278.46%) is below the historical average (-76.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.15 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.60 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.48 Million |
| 2022 | 0.00% | -47.05% | 2.00x | 0.00x | $-1.63 Million |
| 2023 | -145.31% | -16645.29% | 0.01x | 1.43x | $-30.24 Million |
| 2024 | -113.68% | -373362.50% | 0.00x | 1.32x | $-32.50 Million |
| 2025 | -278.46% | -401812.50% | 0.00x | 1.65x | $-33.30 Million |
Industry Comparison
This section compares Genelux Corporation Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genelux Corporation Common Stock (GNLX) | $22.92 Million | 0.00% | 0.41x | $127.80 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Genelux Corporation Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a te… Read more